Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target boosted by analysts at Morgan Stanley from $473.00 to $476.00 in a note issued to investors on Tuesday, Benzinga reports.

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.00% to $475.08 Wednesday, on what proved to be an all-around rough trading ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known ...

At the heart of this biotech boom lies Vertex Pharmaceuticals, a trailblazer that has played a pivotal role in transforming medical landscapes and reshaping patient lives. From groundbreaking ...